Table of contents_4-4.indd

Size: px

Start display at page:

Download "Table of contents_4-4.indd"

みちしげこやぎ
5 years ago
Views:

1 Vol.4 No.4 May 2016

2 Published by Wiley Publishing Japan K.K. The content of this publication contains abstracts and/or translated articles from Movement Disorders, published monthly by the Movement Disorder Society, 555 East Wells Street, Suite 1100 Milwaukee, WI , U.S.A. Copyright 2015 by the Movement Disorder Society. This material is published by Wiley Publishing Japan K.K. with the permission of the Movement Disorder Society. The Movement Disorder Society takes no responsibility for the accuracy of the translation from the published English original and is not liable for any errors which may occur. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner. Japanese edition 2016 ISSN X 2016 Wiley Publishing Japan K.K. Tokyo Office: Frontier Koishikawa Bldg. 4F, Koishikawa, Bunkyo-ku, Tokyo , Japan Telephone: Fax: Internet site: ProductionJapan@wiley.com Associate Commercial Director: Kimiyoshi Ishibashi Production Manager: Shintaro Ashika Project Manager: Yukiko Takahashi Printed and bound in Japan by Souei Co., Ltd.

3 Highlights from the Official Journal of the Movement Disorder Society Vol.4 No.4 May 2016 Contents Selected from Movement Disorders Vol.30 No.11 - No.12, 2015

4 Abstract Disease-Modifying Strategies for Parkinson s Disease Lorraine V. Kalia, MD, PhD,*, **, ***, **** Suneil K. Kalia, MD, PhD, and Anthony E. Lang, MD * Division of Neurology, Department of Medicine, Toronto Western Hospital, University of Toronto, Canada ** Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Canada *** Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson s Disease, Toronto Western Hospital **** Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada Movement Disorders, Vol. 30, No. 11, 2015, pp Parkinson s disease; PD PD PD 3 2 adeno-associated virus serotype; AAV neurturin Q10 PD 8 isradipine 2 AAV glial cell-line derived neurotrophic factor; GDNF α α-synuclein; α-syn 2013 PD PD KEY WORD Table 1 AAV2 2 LS1 Long-term Study 1 PD PPAR peroxisome proliferator-activated receptor PROUD Pramipexole On Underlying Disease QE3 Coenzyme Q10 in Early Parkinson Disease SNpc substantia nigra pars compacta UPDRS Unified Parkinson s Disease Rating Scale Table 1 wileyonlinelibrary.com 2

5 Movement Disorders Vol.4 No.4 Table 2 AAV2 2 GDNF glial cell-line derived neurotrophic factor GM-CSF - granulocyte-macrophage colonystimulating factor GSH glutathione MDS-UPDRS Movement Disorder Society Unified Parkinson s Disease Rating Scale PD UPDRS Unified Parkinson s Disease Rating Scale 3

6 Abstract New Treatments for Levodopa-Induced Motor Complications Olivier Rascol, MD, PhD, *, ** Santiago Perez-Lloret, MD, PhD, and Joaquim J. Ferreira, MD, PhD * Department of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse 3, France ** INSERM CIC1436 and UMR825, Toulouse, France Movement Disorders, Vol. 30, No. 11, 2015, pp Motor fluctuation L- Parkinson s disease; PD L- PD L- L- IPX066 L- motor fluctuation B monoamine oxidase B; MAO-B safinamide -O- catechol-o-methyltransferase; COMT opicapone A 2A istradefylline preladenant tozadenant motor fluctuation II III N - -D- NMDA Eltoprazine mavoglurant mglur5 modulator mavoglurant II KEY WORD 4

7 Movement Disorders Vol.4 No.4 Table 1 DB DD CO CS IR NS OL R UC Good ON-time STN-DBS Table 1 wileyonlinelibrary.com 5

8 Abstract Therapeutic Advances in Multiple System Atrophy and Progressive Supranuclear Palsy Werner Poewe, MD,* Philipp Mahlknecht, MD, PhD, and Florian Krismer, MD *Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria Movement Disorders, Vol. 30, No. 11, 2015, pp multiple system atrophy; MSA progressive supranuclear palsy; PSP 10 MSA PSP MSA α PSP rasagiline MSA MSA tideglusib PSP davunetide PSP 2 MSA MSA PSP KEY WORD Table 1 UMSARS Unified Multiple System Atrophy Rating Scale BDI-II Beck Depression Inventory II EQ-5D EuroQol 5 Dimensions Quality of Life Questionnaire COMPASS Composite Autonomic Symptom Scale CGI Clinical Global Impression MSA-QoL Multiple-System Atrophy Quality of Life Questionnaire Table 1 wileyonlinelibrary.com 6

9 Movement Disorders Vol.4 No.4 Table 4 UMSARS Unified Multiple System Atrophy Rating Scale BDI-II Beck Depression Inventory II EQ-5D EuroQol 5 Dimensions Quality of Life Questionnaire COMPASS Composite Autonomic Symptom Scale CGI Clinical Global Impression OHQ Orthostatic Hypotension Questionnaire OHSA Orthostatic Hypotension Symptom Assessment OHDAS Orthostatic Hypotension Daily Activity Scale MSA-QoL Multiple-System Atrophy Quality of Life Questionnaire BP 7

10 Abstract King s Parkinson s Disease Pain Scale, The First Scale for Pain in PD: An International Validation K. Ray Chaudhuri, MD, DSc, *, **, *** A. Rizos, MSc, C. Trenkwalder, MD, PhD, O. Rascol, MD, PhD, S. Pal, MD, D. Martino, MD, C. Carroll, MD, D. Paviour, MD, C. Falup-Pecurariu, MD, B. Kessel, MD, M. Silverdale, MD, A. Todorova, MD, A. Sauerbier, MD, P. Odin, MD, PhD, A. Antonini, MD, PhD, and P. Martinez-Martin, MD, PhD, on behalf of EUROPAR and the IPMDS Non Motor PD Study Group * King s College Hospital, London, UK * King s College London, London, UK *** University Hospital Lewisham, London, UK Movement Disorders, Vol. 30, No. 12, 2015, pp Parkinson s disease; PD 1 PD PD King s PD Pain Scale 1 one-point-in-time PD 178 ±SD ± ± ± PD 83 King s PD Pain Scale 10 PD 1.48 King s PD Pain Scale 4 57 Kaiser-Mayer-Olkin 0.73 Cronbach α King s PD Pain Scale Scale for Outcomes in PD-Motor Non-Motor Symptoms Scale King s PD Pain Scale PD KEY WORD Table 5b a King s Parkinson s Disease Pain Scale PD SCOPA Scale for Outcomes in PD HADS Hospital Anxiety Depression Rating Scale CISI-PD Clinical Impression of Severity Index in PD LEDD 1 EQ-5D-3L European Quality of Life-5 Dimensions-3 Levels PDQ-8 Parkinson s Disease Questionnaire-8 8

11 Movement Disorders Vol.4 No.4 Table 1 Figure 1 9

12 Movement Disorders Vol.4 No.4 Movement Disorders Vol. 30 No. 11 Reviews Disease-modifying strategies for Parkinson s disease Lorraine V. Kalia, et al. Movement Disorders September : New treatments for levodopa-induced motor complications Olivier Rascol, et al. Movement Disorders September : Advances in functional neurosurgery for Parkinson s disease Leo Verhagen Metman and Konstantin V. Slavin Movement Disorders September : Advances in the treatment of cognitive impairment in Parkinson s disease Jennifer G. Goldman and Daniel Weintraub Movement Disorders September : New clinical trials for nonmotor manifestations of Parkinson s disease Anette Schrag, et al. Movement Disorders September : Nonpharmacological treatments for patients with Parkinson s disease Bastiaan R. Bloem, et al. Movement Disorders September : Basic science breaks through: New therapeutic advances in Parkinson s disease Patrik Brundin, et al. Movement Disorders September : Therapeutic advances in multiple system atrophy and progressive supranuclear palsy Werner Poewe, et al. Movement Disorders September : Therapeutic advances in Huntington s Disease Kathleen M. Shannon and Avram Fraint Movement Disorders September : Therapeutic advances in dystonia Alberto Albanese, et al. Movement Disorders September : Therapeutic advances in tremor Alfonso Fasano and Günther Deuschl Movement Disorders September : Therapeutic Developments for Tics and Myoclonus Joseph Jankovic Movement Disorders September : Therapeutic advances in restless legs syndrome (RLS) Birgit Högl and Cynthia Comella Movement Disorders September : Advances in clinical trials for movement disorders Karl Kieburtz and C. Warren Olanow Movement Disorders September : Movement Disorders Vol. 30 No. 12 Reviews MDS clinical diagnostic criteria for Parkinson s disease Ronald B. Postuma, et al. Movement Disorders October : MDS research criteria for prodromal Parkinson s disease Daniela Berg, et al. Movement Disorders October : Scientific Perspectives Structural studies of parkin and sacsin: Mitochondrial dynamics in neurodegenerative diseases Xinlu Li and Kalle Gehring Movement Disorders October : Hot Topics Targeting glucocerebrosidase: Reduced enzymatic activity and Parkinson s disease Kishore Raj Kumar Movement Disorders October :1620 Gardening gone awry: Aberrant spine pruning disrupts longrange networks Frank Leypoldt and Alexander Münchau Movement Disorders October :1621 Hot topic: Recessive mutations in the a3(vi) collagen gene COL6A3 cause early-onset isolated dystonia Bettina Balint and Kailash P. Bhatia Movement Disorders October :1622 Research Articles King s Parkinson s disease pain scale, the first scale for pain in PD: An international validation K. Ray Chaudhuri, et al. Movement Disorders October : Handling missing values in the MDS-UPDRS Christopher G. Goetz, et al. Movement Disorders October : Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson s disease Karen E. Murphy, et al. Movement Disorders October : Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson s disease patients Christine R. Swanson, et al. Movement Disorders October : Exercise improves cognition in Parkinson s disease: The PRET-PD randomized, clinical trial Fabian J. David, et al. Movement Disorders October : Multivariate prediction of motor diagnosis in Huntington s disease: 12 years of PREDICT-HD Jeffrey D. Long, et al. Movement Disorders October :

13 Movement Disorders Vol.4 No.4 Essential and aging-related tremor: Differences of central control Muthuraman Muthuraman, et al. Movement Disorders October : NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study Christopher F. O Brien, et al. Movement Disorders October : Brief Reports Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy Kathrin Doppler, et al. Movement Disorders October : A novel retinal biomarker for Parkinson s disease: Quantifying the foveal pit with optical coherence tomography Samantha Slotnick, et al. Movement Disorders October : A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson s disease Laurie K. Mischley, et al. Movement Disorders October : Cerebellar transcranial direct current stimulation in patients with ataxia: A double-blind, randomized, sham-controlled study Alberto Benussi, et al. Movement Disorders October : Premotor motor excitability is altered in dopa-responsive dystonia Anne Weissbach, et al. Movement Disorders October :

P.1~18

P.1~18 JCM Copyright 2011 Japanese by JCM Copyright 2008 bymelvin W Wong Published by ARMOUR Publishing Pte Ltd Kent Ridge Post Office P.O.Box 1193,Singapore 911107 Email: mail@armourpublishing.com Website: www.armourpublising.com